Related Experiment Video
Updated: Jan 25, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C
Ramazan Idilman1, Maria Nicola De, Alessandra Colantoni
1Department of Medicine, Loyola University Medical Center, Maywood, Illinois, USA.
Insights
High-dose, short-interval hepatitis B virus (HBV) vaccination is safe and effective for individuals with chronic hepatitis C (HCV). This vaccination schedule can elicit an early antibody response, improving protection against HBV in this vulnerable population.
Area of Science:
- Hepatology
- Immunology
- Vaccinology
Background:
- Standard hepatitis B virus (HBV) vaccination efficacy is reduced in individuals with chronic hepatitis C (HCV).
- Assessing alternative vaccination schedules is crucial for improving HBV protection in HCV patients.
Purpose of the Study:
- To evaluate the response rate to a high-dose, short-interval HBV vaccination in individuals with chronic hepatitis C.
- To determine the safety and immunogenicity of this enhanced vaccination schedule.
Main Methods:
- 152 individuals with chronic hepatitis C received 40 microg of HBV vaccine monthly for 3 months.
- A control group of 26 healthy individuals received the same schedule.
- Non-responders received an 80 microg booster dose.
Main Results:
- 72% of chronic hepatitis C patients seroconverted, compared to 92% in controls.
- Effective immunity (>100 mIU/ml) showed no significant difference between groups (51% vs 54%).
- Response rates were lower in cirrhotics (54%) than non-cirrhotics (80%), but improved after a booster dose (74% vs 88%). No major adverse effects were observed.
Conclusions:
- A high-dose, short-interval HBV vaccination schedule is safe for individuals with chronic hepatitis C.
- This schedule can induce an effective and early antibody response, enhancing HBV protection in this population.
Objectives:
The efficacy of the standard hepatitis B virus (HBV) vaccination schedule in individuals with chronic hepatitis C is reported to be reduced. Our aim was to assess the response rate to high dose, short interval HBV vaccination in such individuals.
Methods:
A total of 152 individuals with chronic hepatitis C were vaccinated with 40 microg of vaccine administered monthly for 3 months. Twenty-six individuals with no evidence of liver disease underwent the same vaccination schedule and were considered to be the control group. Hepatitis C virus (HCV)-positive subjects who did not seroconvert to anti-hepatitis B surface positivity after the third dose of the vaccine (nonresponder) were vaccinated with a fourth dose of vaccine (booster dose, 80 microg).
Results:
One hundred nine of the 152 individuals with chronic hepatitis C (72%) seroconverted to anti-hepatitis B surface positivity (> 10 mIU/ml), as compared to 24 of the 26 controls (92%, p < 0.05). Although individuals with chronic hepatitis C responded less frequently to high dose, short interval HBV vaccination than did the controls, no differences in terms of effective immunity (>100 mIU/ml) were evident among the two groups of responders (51% vs 54%). Also, no difference in response was reported between individuals with chronic active hepatitis C and controls (92% vs 80%). The response rate was significantly lower in cirrhotics than in the noncirrhotic group (54% vs 80%, p < 0.001). Besides cirrhosis, no other demographic or bioclinical factor was found to influence the response to vaccination. After the additional booster dose, the overall response was increased to 74% of the cirrhotics and 88% of the noncirrhotics. No major HBV vaccine-related adverse effects were seen.
Conclusions:
A high dose, short interval HBV vaccination schedule is safe in individuals with chronic hepatitis C. From these data, it is suggested that a high dose and a short interval between HBV vaccinations may produce an effective and early antibody response in such patients.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Impact of Individuals on Individuals
Vaccinations
Prediction Intervals
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y.
Confidence Intervals
A...

